Evolving Treatment Landscape for mHSPC: Latest Clinical Data and Implications for Practice

Did you know androgen deprivation monotherapy is no longer considered standard of care for metastatic hormone-sensitive prostate cancer (mHSPC) by experts?

Credit available for this activity expires: 11/25/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001957?ecd=bdc_podcast_libsyn_mscpedu